XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.22.1

Earnings Per Common Share | 3 Months Ended
--- | ---
Mar. 31, 2022
Earnings Per Share [Abstract] |
Earnings Per Common Share | Earnings Per Common Share Basic income (loss) per common share (“EPS”) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method and common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company’s basic income (loss) per share are included in diluted income (loss) per share during the periods presented. Restricted stock and certain performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share. Refer to Note 11 for a discussion of the sale of shares under and settlement of forward sales agreements during the periods presented. The Company considered the potential dilution resulting from the forward agreements to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. The aggregate effect on the Company’s diluted weighted-average common shares for the three months ended March 31, 2022 and 2021 was zero weighted-average incremental shares from the forward equity sales agreements. The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):
| Three Months Ended March 31, |  |
| 2022 |  | 2021 |  |  |  |
Numerator |  |  |  |  |  |  |
Income (loss) from continuing operations | $ | 75,026 |  |  | $ | (120,585) |  |  |  |  |
Noncontrolling interests' share in continuing operations | (3,730) |  |  | (3,306) |  |  |  |  |
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc. | 71,296 |  |  | (123,891) |  |  |  |  |
Less: Participating securities' share in continuing operations | (1,976) |  |  | (2,451) |  |  |  |  |
Income (loss) from continuing operations applicable to common shares | 69,320 |  |  | (126,342) |  |  |  |  |
Income (loss) from discontinued operations | 317 |  |  | 270,008 |  |  |  |  |
Noncontrolling interests' share in discontinued operations | — |  |  | (329) |  |  |  |  |
Net income (loss) applicable to common shares | $ | 69,637 |  |  | $ | 143,337 |  |  |  |  |
Denominator |  |  |  |  |  |  |
Basic weighted average shares outstanding | 539,352 |  |  | 538,679 |  |  |  |  |
Dilutive potential common shares - equity awards(1) | 234 |  |  | — |  |  |  |  |
Diluted weighted average common shares | 539,586 |  |  | 538,679 |  |  |  |  |
Basic earnings (loss) per common share |  |  |  |  |  |  |
Continuing operations | $ | 0.13 |  |  | $ | (0.23) |  |  |  |  |
Discontinued operations | 0.00 |  |  | 0.50 |  |  |  |  |
Net income (loss) applicable to common shares | $ | 0.13 |  |  | $ | 0.27 |  |  |  |  |
Diluted earnings (loss) per common share |  |  |  |  |  |  |
Continuing operations | $ | 0.13 |  |  | $ | (0.23) |  |  |  |  |
Discontinued operations | 0.00 |  |  | 0.50 |  |  |  |  |
Net income (loss) applicable to common shares | $ | 0.13 |  |  | $ | 0.27 |  |  |  |  |
_______________________________________ (1)For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options). For the three months ended March 31, 2022, the 9.1 million shares under forward sales agreements that have not been settled as of March 31, 2022 were anti-dilutive. For the three months ended March 31, 2021, forward sales agreements had no dilutive impact as no shares remained outstanding under ATM forward contracts during the period.For the three months ended March 31, 2022 and 2021, all 7 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration